查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1709462

神經保護市場，按產品類型、按疾病適應症、按作用機制、按最終用戶、按國家和地區分類 - 2025 年至 2032 年全球行業分析、市場規模、市場佔有率和預測

Neuroprotection Market, By Product Type, By Disease Indication, By Mechanism of Action, By End User, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 309 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告重點

2024 年神經保護市場規模價值 340.9243 億美元，2025 年至 2032 年的複合年成長率為 7.42%。

該市場的成長是由神經系統疾病盛行率的不斷上升、醫學研究的進步以及對有效治療的需求的不斷成長所推動的。此外，隨著神經退化性疾病變得越來越普遍，全球人口老化進一步刺激了市場的發展。各公司正大力投資創新解決方案，以不斷擴大神經保護領域的治療選擇範圍。

神經保護市場-市場動態

早期神經退化性疾病診斷的生物標記發現的進展。

生物標記發現的進步在神經退化性疾病的早期診斷中發揮關鍵作用，極大地推動了神經保護市場的發展。生物標記有助於在神經系統疾病發作時檢測出來，從而能夠更早、更有效地進行干預，這對於改善患者的預後至關重要。這些發現促進了個人化治療方法，因為生物標記可以識別特定的疾病亞型並預測進展。提高診斷精度可以確保及時治療和更好的管理，從而降低醫療成本。

學術機構和研究組織正在引領這一進程，並透過合作推動突破。例如，美國國家老化研究所（NIA）正在積極資助阿茲海默症的生物標記研究，這已經促成了幾種有前景的診斷標誌物的開發。據 NIA 稱，每年撥款超過 3 億美元用於阿茲海默症研究，其中大部分資金集中在生物標記的進展。這些發展不僅提高了診斷的準確性，而且支持了神經退化性疾病治療中精準醫療的更廣泛趨勢。

神經保護市場—關鍵洞察

根據我們的研究分析師的分析，預計全球市場在預測期內（2025-2032 年）的年複合成長率約為 7.42%。

根據產品類型細分，預計 2024 年藥物將佔據最大市場佔有率

根據疾病適應症細分，阿茲海默症是 2024 年最主要的疾病適應症

根據作用機轉細分，抗氧化劑是 2024 年最主要的作用機制

根據最終用戶細分，醫院是 2024 年領先的最終用戶

按地區分類，北美是 2024 年的主要收入來源

神經保護市場-細分分析：

全球神經保護市場根據產品類型、疾病適應症、作用機制、最終用戶和地區進行細分。

根據產品類型，市場分為兩類：藥物和設備。在神經保護市場中，藥物是最重要的部分。由於它們在治療阿茲海默症、帕金森氏症和多發性硬化症等神經系統疾病和病症方面發揮直接作用，因此佔據了市場主導地位。包括神經保護藥物在內的藥物旨在減緩疾病進展、保護神經元免受損害並改善患者的生活品質。該領域受益於正在進行的研究、臨床試驗和監管部門的批准，推動了對新型藥物治療的需求。隨著神經科學的進步帶來更有效的治療方法，神經保護藥物市場預計將繼續成長。

根據疾病適應症，市場分為六類：帕金森氏症、阿茲海默症、中風、多發性硬化症、肌萎縮側索硬化症 (ALS)、創傷性腦損傷 (TBI)、其他。在神經保護市場中，阿茲海默症是最重要的疾病適應症。由於該疾病在世界範圍內的流行率很高，且人口老化日益加劇，因此它佔據了最大的佔有率。阿茲海默症會引發廣泛的神經退化性病變，對旨在減緩其進展的神經保護療法的需求龐大。藥物開發的不斷進步和對尋找有效治療方法的日益關注推動了這一領域的發展。隨著對創新治療的需求不斷成長，阿茲海默症仍然是研究人員和製藥公司的焦點。

神經保護市場—地理洞察

受人口老化、阿茲海默症、帕金森氏症和多發性硬化症等神經退化性疾病盛行率上升以及生物技術和製藥業的進步推動，北美神經保護市場正在經歷顯著成長。美國佔最大佔有率，這得益於其強大的醫療保健基礎設施、大量的研究資金以及對治療方案的高需求。加拿大也透過加大對神經保護研究和開發的投資為市場做出了貢獻。此外，人們越來越關注早期介入和預防治療以及新興藥物療法。政府措施以及學術機構和私營部門之間的合作正在促進神經保護劑的創新。然而，藥物開發成本高和監管障礙等挑戰依然存在。儘管如此，市場前景依然樂觀，行業主要參與者正在探索新的治療策略來滿足未滿足的醫療需求。

美國是北美神經保護市場的主導國家，這主要歸功於其先進的醫療保健系統、高水準的研發以及政府對醫療創新的大量資助。該國擁有許多專注於神經退化性疾病的領先生物技術和製藥公司，為神經保護療法的快速發展和商業化做出了貢獻。此外，美國人口數量龐大且老化，對治療的需求不斷成長，成為市場成長的主要驅動力。

神經保護市場-競爭格局：

神經保護市場的競爭格局以製藥公司、生技公司和研究機構之間的激烈競爭為特徵，它們都在爭相開發治療神經系統疾病的有效方法。百健（Biogen）、諾華（Novartis）和禮來（Eli Lilly）等主要公司憑藉其成熟的產品組合在阿茲海默症和帕金森氏症等神經退化性疾病領域佔據主導地位。公司正專注於創新藥物的發現，針對神經發炎和神經再生等新機制。市場也看到大型製藥公司和小型生物技術公司之間的合作，以利用基因治療和幹細胞研究等先進技術。

神經退化性疾病的發生率不斷上升以及對改進治療方法的需求推動了市場佔有率的激烈競爭。法規核准流程和高昂的研發成本增加了複雜性，導致市場只剩下少數幾個擁有大量資源和專業知識的主導者。新進者不斷尋找利基領域和突破性療法來使自己脫穎而出。

最新動態：

2023 年 11 月，美國食品藥物管理局 (FDA) 與 BrainStorm Cell Therapeutics 會面，討論 NurOwn，一種有可能緩解 ALS 症狀的設備。會議討論了潛在確認性 III 期試驗的總體方案設計。

目錄

第1章：神經保護市場概述

  • 研究範圍
  • 市場估計年限

第2章：執行摘要

  • 市場片段
    • 神經保護市場片段（依產品類型）
    • 神經保護市場片段（按疾病適應症）
    • 神經保護市場片段（依作用機制）
    • 神經保護市場片段（按最終用戶）
    • 神經保護市場（按國家/地區）
    • 神經保護市場（按地區）
  • 競爭洞察

第3章：神經保護關鍵市場趨勢

  • 神經保護市場促進因素
    • 市場促進因素的影響分析
  • 神經保護市場限制
    • 市場限制的影響分析
  • 神經保護市場機會
  • 神經保護市場未來趨勢

第4章：神經保護產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：神經保護市場：地緣政治緊張局勢升級的影響

  • COVID-19 疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：神經保護市場格局

  • 2024年神經保護市場佔有率分析
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第7章：神經保護市場－依產品類型

  • 概述
    • 按產品類型分類的細分市場佔有率分析
    • 藥物
      • 抗氧化劑
      • 抗發炎藥物
      • 鈣通道阻斷劑
      • 自由基清除劑
    • 裝置

第 8 章：神經保護市場 - 按疾病適應症

  • 概述
    • 按疾病適應症分類的細分佔有率分析
    • 帕金森氏症
    • 阿茲海默症
    • 中風
    • 多發性硬化症
    • 肌萎縮側索硬化症（ALS）
    • 創傷性腦損傷（TBI）
    • 其他

第9章：神經保護市場－按作用機制

  • 概述
    • 依作用機制分析細分市場佔有率
    • 抗氧化劑
    • 粒線體保護
    • 發炎調節
    • 鈣調節
    • 神經發生刺激
    • 基於基因治療

第 10 章：神經保護市場 - 按最終用戶

  • 概述
    • 按最終用戶細分的佔有率分析
    • 醫院
    • 診所
    • 研究機構
    • 居家照護環境

第 11 章：神經保護市場 - 按地區分類

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美神經保育關鍵製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模和預測（按產品類型）
    • 北美市場規模及預測（依疾病類型分類）
    • 北美市場規模及預測（按作用機制）
    • 北美市場規模和預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲神經保護關鍵製造商
    • 歐洲市場規模及預測（按國家/地區）
    • 歐洲市場規模和預測（按產品類型）
    • 歐洲市場規模及預測（依疾病類型分類）
    • 歐洲市場規模及預測（按作用機制）
    • 歐洲市場規模和預測（按最終用戶）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區神經保護關鍵製造商
    • 亞太地區市場規模及預測（依國家）
    • 亞太地區市場規模及預測（依產品類型）
    • 亞太地區市場規模及預測（依疾病類型分類）
    • 亞太地區市場規模及預測（依作用機制）
    • 亞太地區市場規模及預測（依最終用戶）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲神經保護關鍵製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（依產品類型）
    • 拉丁美洲市場規模及預測（依疾病類型分類）
    • 拉丁美洲市場規模及預測（依作用機制）
    • 拉丁美洲市場規模及預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲（MEA）
    • 概述
    • 中東和非洲的神經保護關鍵製造商
    • MEA 市場規模及預測（依國家/地區）
    • MEA 市場規模及預測（依產品類型）
    • MEA 市場規模及預測（依疾病類型分類）
    • MEA 市場規模及預測（依作用機制）
    • MEA 市場規模和預測（按最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其餘地區

第 12 章：關鍵供應商分析-神經保護產業

  • 競爭儀錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司簡介
    • Biogen Inc.
    • Eli Lilly and Co.
    • Novartis AG
    • Roche Holding AG
    • Merck & Co.
    • Pfizer Inc.
    • Amgen Inc.
    • AbbVie Inc.
    • Johnson & Johnson
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Limited
    • Lundbeck A/S
    • GlaxoSmithKline (GSK)
    • AstraZeneca plc
    • Eisai Co., Ltd.
    • Neurocrine Biosciences, Inc.
    • Axovant Gene Therapies

第 13 章：360 度分析師視角

第 14 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4932

REPORT HIGHLIGHT

Neuroprotection Market size was valued at US$ 34,092.43 Million in 2024, expanding at a CAGR of 7.42% from 2025 to 2032.

The neuroprotection market refers to the industry focused on developing therapies and products aimed at protecting the nervous system, particularly the brain and spinal cord, from damage caused by diseases, injuries, or aging. This market addresses conditions such as Alzheimer's disease, Parkinson's disease, stroke, multiple sclerosis, and traumatic brain injuries. Neuroprotective treatments can involve drug therapies, antioxidants, neurotrophic factors, and other interventions that help prevent or reduce neuronal damage.

The growth of this market is driven by the increasing prevalence of neurological disorders, advances in medical research, and the rising demand for effective treatments. Additionally, the aging global population further fuels the market as neurodegenerative diseases become more common. Companies are heavily investing in innovative solutions, leading to an expanding range of therapeutic options in neuroprotection.

Neuroprotection Market- Market Dynamics

Advancements in biomarker discovery for early-stage neurodegenerative disease diagnosis.

Advancements in biomarker discovery play a critical role in the early diagnosis of neurodegenerative diseases, significantly driving the neuroprotection market. Biomarkers help detect neurological disorders at their onset, enabling earlier and more effective intervention, which is crucial for improving patient outcomes. These discoveries facilitate personalized treatment approaches, as biomarkers can identify specific disease subtypes and predict progression. Enhanced diagnostic precision can reduce healthcare costs by ensuring timely therapies and better management.

Academic institutions and research organizations are leading the charge, with collaborations fostering breakthroughs. For instance, the National Institute on Aging (NIA) in the U.S. is actively funding biomarker research for Alzheimer's disease, which has led to the development of several promising diagnostic markers. According to the NIA, over $300 million is allocated annually toward Alzheimer's research, much of which focuses on biomarker advancements. These developments not only enhance diagnostic accuracy but also support the broader trend of precision medicine in neurodegenerative care.

Neuroprotection Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.42% over the forecast period (2025-2032)

Based on product type segmentation, Medications was predicted to show maximum market share in the year 2024

Based on Disease Indication segmentation, Alzheimer's disease was the leading Disease Indication in 2024

Based on Mechanism of Action segmentation, Antioxidants was the leading Mechanism of Action in 2024

Based on End-User segmentation, Hospitals was the leading End-User in 2024

On the basis of region, North America was the leading revenue generator in 2024

Neuroprotection Market- Segmentation Analysis:

The Global Neuroprotection Market is segmented on the basis of Product Type, Disease Indication, Mechanism of Action, End User, and Region.

The market is divided into two categories based on product type: Medication and Devices. In the neuroprotection market, medications are the most significant segment. They dominate the market due to their direct role in treating neurological diseases and conditions like Alzheimer's, Parkinson's, and multiple sclerosis. Medications, including neuroprotective drugs, are designed to slow disease progression, protect neurons from damage, and improve patients' quality of life. This segment benefits from ongoing research, clinical trials, and regulatory approvals, driving demand for novel pharmaceutical treatments. The market for neuroprotective medications is expected to continue growing as advancements in neuroscience lead to more effective therapies.

The market is divided into six categories based on Disease Indication: Parkinson's Disease, Alzheimer's Disease, Stroke, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI), Others. In the neuroprotection market, Alzheimer's disease is the most significant disease indication. It holds the largest share due to the high prevalence of the disease worldwide and the increasing aging population. Alzheimer's triggers widespread neurodegeneration, creating a substantial demand for neuroprotective therapies aimed at slowing its progression. Ongoing advancements in drug development and the increasing focus on finding effective treatments have propelled this segment forward. As the need for innovative treatments grows, Alzheimer's disease remains a focal point for researchers and pharmaceutical companies.

Neuroprotection Market- Geographical Insights

The North American neuroprotection market is experiencing significant growth, driven by an aging population, increasing prevalence of neurodegenerative diseases like Alzheimer's, Parkinson's, and multiple sclerosis, and advances in biotechnology and pharmaceuticals. The U.S. holds the largest share, owing to strong healthcare infrastructure, substantial research funding, and a high demand for therapeutic solutions. Canada is also contributing to the market with growing investments in neuroprotective research and development. Furthermore, there is a rising focus on early-stage interventions and preventative treatments, as well as emerging drug therapies. Government initiatives and collaborations between academic institutions and private sectors are enhancing innovation in neuroprotective agents. However, challenges such as high drug development costs and regulatory hurdles remain. Despite this, the market outlook remains optimistic, with key players in the industry exploring novel treatment strategies to address unmet medical needs.

The United States is the dominant country in the North American neuroprotection market, largely due to its advanced healthcare system, high level of research and development, and substantial government funding for medical innovation. The country is home to many leading biotech and pharmaceutical companies focused on neurodegenerative diseases, contributing to the rapid development and commercialization of neuroprotective therapies. Additionally, the large and aging population in the U.S. presents a growing demand for treatments, making it a key driver of market growth.

Neuroprotection Market- Competitive Landscape:

The competitive landscape of the neuroprotection market is characterized by intense rivalry among pharmaceutical companies, biotech firms, and research institutions, all vying to develop effective treatments for neurological disorders. Major players such as Biogen, Novartis, and Eli Lilly dominate with established portfolios in neurodegenerative diseases like Alzheimer's and Parkinson's. Companies are focusing on innovative drug discovery, targeting new mechanisms like neuroinflammation and neuroregeneration. The market also sees collaborations between large pharmaceutical firms and smaller biotech companies to leverage advanced technologies like gene therapy and stem cell research.

The increasing prevalence of neurodegenerative diseases and the need for improved treatments drive fierce competition for market share. Regulatory approval processes and the high cost of R&D add layers of complexity, leading to a few dominant players with significant resources and expertise. New entrants are constantly looking for niche areas and breakthrough therapies to differentiate themselves.

Recent Developments:

In November 2023, the US Food and Drug Administration (FDA) met with BrainStorm Cell Therapeutics to discuss NurOwn, a device with the potential to alleviate symptoms of ALS. The meeting discussed the overall protocol design of a potential confirmatory Phase III trial.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEUROPROTECTION MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Biogen Inc.
  • Eli Lilly and Co.
  • Novartis AG
  • Roche Holding AG
  • Merck & Co.
  • Pfizer Inc.
  • Amgen Inc.
  • AbbVie Inc.
  • Johnson & Johnson
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Lundbeck A/S
  • GlaxoSmithKline (GSK)
  • AstraZeneca plc
  • Eisai Co., Ltd.
  • Neurocrine Biosciences, Inc.
  • Axovant Gene Therapies

GLOBALNEUROPROTECTION MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Medication
  • Antioxidants
  • Anti-inflammatory drugs
  • Calcium channel blockers
  • Free radical scavengers
  • Devices

GLOBAL NEUROPROTECTION MARKET, BY DISEASE INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Parkinson's Disease
  • Alzheimer's Disease
  • Stroke
  • Multiple Sclerosis
  • Amyotrophic Lateral Sclerosis (ALS)
  • Traumatic Brain Injury (TBI)
  • Others

GLOBAL NEUROPROTECTION MARKET, BY MECHANISM OF ACTION- MARKET ANALYSIS, 2019 - 2032

  • Antioxidants
  • Mitochondrial Protection
  • Inflammation Modulation
  • Calcium Regulation
  • Neurogenesis Stimulation
  • Gene Therapy-Based

GLOBAL NEUROPROTECTION MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Clinics
  • Research Institutes
  • Home Care Settings

GLOBAL NEUROPROTECTION MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Neuroprotection Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Neuroprotection Market Snippet by Product Type
    • 2.1.2. Neuroprotection Market Snippet by Disease Indication
    • 2.1.3. Neuroprotection Market Snippet by Mechanism of Action
    • 2.1.4. Neuroprotection Market Snippet by End User
    • 2.1.5. Neuroprotection Market Snippet by Country
    • 2.1.6. Neuroprotection Market Snippet by Region
  • 2.2. Competitive Insights

3. Neuroprotection Key Market Trends

  • 3.1. Neuroprotection Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Neuroprotection Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Neuroprotection Market Opportunities
  • 3.4. Neuroprotection Market Future Trends

4. Neuroprotection Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Neuroprotection Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Neuroprotection Market Landscape

  • 6.1. Neuroprotection Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Neuroprotection Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
    • 7.1.2. Medication
      • 7.1.2.1. Antioxidants
      • 7.1.2.2. Anti-inflammatory drugs
      • 7.1.2.3. Calcium channel blockers
      • 7.1.2.4. Free radical scavengers
    • 7.1.3. Devices

8. Neuroprotection Market - By Disease Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Disease Indication, 2024 & 2032 (%)
    • 8.1.2. Parkinson's Disease
    • 8.1.3. Alzheimer's Disease
    • 8.1.4. Stroke
    • 8.1.5. Multiple Sclerosis
    • 8.1.6. Amyotrophic Lateral Sclerosis (ALS)
    • 8.1.7. Traumatic Brain Injury (TBI)
    • 8.1.8. Others

9. Neuroprotection Market - By Mechanism of Action

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Mechanism of Action, 2024 & 2032 (%)
    • 9.1.2. Antioxidants
    • 9.1.3. Mitochondrial Protection
    • 9.1.4. Inflammation Modulation
    • 9.1.5. Calcium Regulation
    • 9.1.6. Neurogenesis Stimulation
    • 9.1.7. Gene Therapy-Based

10. Neuroprotection Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Clinics
    • 10.1.4. Research Institutes
    • 10.1.5. Home Care Settings

11. Neuroprotection Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Neuroprotection Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Neuroprotection Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Neuroprotection Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Neuroprotection Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Neuroprotection Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Neuroprotection Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Biogen Inc.
    • 12.2.2. Eli Lilly and Co.
    • 12.2.3. Novartis AG
    • 12.2.4. Roche Holding AG
    • 12.2.5. Merck & Co.
    • 12.2.6. Pfizer Inc.
    • 12.2.7. Amgen Inc.
    • 12.2.8. AbbVie Inc.
    • 12.2.9. Johnson & Johnson
    • 12.2.10. Sanofi S.A.
    • 12.2.11. Teva Pharmaceutical Industries Ltd.
    • 12.2.12. Takeda Pharmaceutical Company Limited
    • 12.2.13. Lundbeck A/S
    • 12.2.14. GlaxoSmithKline (GSK)
    • 12.2.15. AstraZeneca plc
    • 12.2.16. Eisai Co., Ltd.
    • 12.2.17. Neurocrine Biosciences, Inc.
    • 12.2.18. Axovant Gene Therapies

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us